---
document_datetime: 2025-12-02 05:20:40
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/idefirix.html
document_name: idefirix.html
version: success
processing_time: 0.1039775
conversion_datetime: 2025-12-25 02:00:54.994702
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Idefirix

[RSS](/en/individual-human-medicine.xml/67340)

##### Authorised

This medicine is authorised for use in the European Union

imlifidase Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Idefirix](#news-on)
- [More information on Idefirix](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Idefirix is a medicine used to prevent the body from rejecting a newly transplanted kidney.

Idefirix is used before transplantation in adults who have antibodies against the donor kidney and are considered 'highly sensitised' based on a positive crossmatch test. It should be reserved for patients who are unlikely to obtain a transplant under the available kidney allocation system.

Graft organ rejection following solid organ transplantation is rare, and Idefirix was designated an 'orphan medicine' (a medicine used in rare diseases) on 12 January 2017.

Idefirix contains the active substance imlifidase.

Expand section

Collapse section

## How is Idefirix used?

Idefirix is for hospital use only and can only be obtained with a prescription. Idefirix treatment should only be prescribed and supervised by a doctor experienced in the use of immunosuppressive medicines (medicines that reduce the activity of the immune system, the body's natural defences) and in the management of sensitised kidney transplant patients.

Idefirix is given as an infusion (drip) into a vein. The medicine is given as a single dose in the 24 hours before transplantation. If necessary, a second dose can be given within 24 hours after the first dose.

Patients treated with Idefirix still require standard immunosuppressive therapy after kidney transplantation.

For more information about using Idefirix, see the package leaflet or contact your doctor or pharmacist.

## How does Idefirix work?

Highly sensitised patients have high levels of antibodies (proteins in the blood that fight infections and other foreign cells) against the donor's tissue, including immunoglobulin G (IgG) antibodies. This makes their body more likely to reject the donor organ. The active substance in Idefirix, imlifidase, is an enzyme (a protein) that breaks down the IgG antibodies, thereby reducing the likelihood of the body rejecting the donor kidney.

## What benefits of Idefirix have been shown in studies?

Idefirix was investigated in one main study of 19 patients with end-stage kidney disease who were highly sensitised to the donor kidney based on a positive crossmatch test. Within 24 hours of receiving Idefirix, 17 of the patients became crossmatch-negative and one was borderline crossmatch-positive, making all 18 eligible for kidney transplantation. A total of 16 patients  had a functioning kidney 6 months after transplantation.

Additional data on the benefits of Idefirix came from three supportive studies. Analyses of the data from all four studies showed that 43 out of a total of 46 patients  had a functioning kidney 6 months after transplantation.

## What are the risks associated with Idefirix?

The most common side effects with Idefirix (which may affect more than 1 in 10 people) are infections, including pneumonia (infection of the lungs), urinary tract infection and sepsis (blood poisoning). Other common side effects (which may affect up to 1 in 10 people) are pain and reactions around the infusion site, increased blood levels of certain liver enzymes, muscle pain, headache and flushing.

The most common serious side effects with Idefirix (which may affect up to 1 in 10 people) are pneumonia and sepsis.

Idefirix should not be used in people with a serious infection or thrombotic thrombocytopenic purpura.

For the full list of side effects and restrictions, see the package leaflet.

## Why is Idefirix authorised in the EU?

The European Medicines Agency decided that Idefirix's benefits are greater than its risks and it can be authorised for use in the EU.

Antibodies against the donor's graft are a major obstacle to successful transplantation in patients with kidney failure. Patients who are highly sensitised therefore usually remain on dialysis with shorter life expectancy and poor quality of life. In light of this unmet medical need and despite the need for further data, the Agency considered that the available evidence suggests that Idefirix is effective at reducing antibody levels in highly sensitised adults, allowing them to receive a kidney transplant. The safety profile of Idefirix is considered manageable.

Idefirix has been given 'conditional authorisation'. This means that there is more evidence to come about the medicine, which the company is required to provide. Every year, the Agency will review any new information that becomes available and this overview will be updated as necessary.

## What information is still awaited for Idefirix?

Since Idefirix has been given conditional authorisation, the company that markets Idefirix will provide additional data from an ongoing study into the long-term graft functioning and survival in patients who have undergone kidney transplantation after Idefirix treatment. The company will also provide data from a new study to confirm the long-term effectiveness and safety of Idefirix.

## What measures are being taken to ensure the safe and effective use of Idefirix?

The company that markets Idefirix will provide results of a long-term study of Idefirix to confirm its effectiveness.

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Idefirix have also been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Idefirix are continuously monitored. Side effects reported with Idefirix are carefully evaluated and any necessary action taken to protect patients.

## Other information about Idefirix

Idefirix received a conditional marketing authorisation valid throughout the EU on 25 August 2020.

Idefirix : EPAR - Medicine overview

Reference Number: EMA/351276/2020

English (EN) (121.66 KB - PDF)

**First published:** 28/08/2020

[View](/en/documents/overview/idefirix-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-136)

български (BG) (125.15 KB - PDF)

**First published:**

28/08/2020

[View](/bg/documents/overview/idefirix-epar-medicine-overview_bg.pdf)

español (ES) (102.42 KB - PDF)

**First published:**

28/08/2020

[View](/es/documents/overview/idefirix-epar-medicine-overview_es.pdf)

čeština (CS) (121.89 KB - PDF)

**First published:**

28/08/2020

[View](/cs/documents/overview/idefirix-epar-medicine-overview_cs.pdf)

dansk (DA) (101.71 KB - PDF)

**First published:**

28/08/2020

[View](/da/documents/overview/idefirix-epar-medicine-overview_da.pdf)

Deutsch (DE) (102.55 KB - PDF)

**First published:**

28/08/2020

[View](/de/documents/overview/idefirix-epar-medicine-overview_de.pdf)

eesti keel (ET) (99.79 KB - PDF)

**First published:**

28/08/2020

[View](/et/documents/overview/idefirix-epar-medicine-overview_et.pdf)

ελληνικά (EL) (131.78 KB - PDF)

**First published:**

28/08/2020

[View](/el/documents/overview/idefirix-epar-medicine-overview_el.pdf)

français (FR) (102.69 KB - PDF)

**First published:**

28/08/2020

[View](/fr/documents/overview/idefirix-epar-medicine-overview_fr.pdf)

hrvatski (HR) (116.49 KB - PDF)

**First published:**

28/08/2020

[View](/hr/documents/overview/idefirix-epar-medicine-overview_hr.pdf)

italiano (IT) (101.93 KB - PDF)

**First published:**

28/08/2020

[View](/it/documents/overview/idefirix-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (129.33 KB - PDF)

**First published:**

28/08/2020

[View](/lv/documents/overview/idefirix-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (127.5 KB - PDF)

**First published:**

28/08/2020

[View](/lt/documents/overview/idefirix-epar-medicine-overview_lt.pdf)

magyar (HU) (115.86 KB - PDF)

**First published:**

28/08/2020

[View](/hu/documents/overview/idefirix-epar-medicine-overview_hu.pdf)

Malti (MT) (121.75 KB - PDF)

**First published:**

28/08/2020

[View](/mt/documents/overview/idefirix-epar-medicine-overview_mt.pdf)

Nederlands (NL) (102.23 KB - PDF)

**First published:**

28/08/2020

[View](/nl/documents/overview/idefirix-epar-medicine-overview_nl.pdf)

polski (PL) (44.7 KB - PDF)

**First published:**

28/08/2020

[View](/pl/documents/overview/idefirix-epar-medicine-overview_pl.pdf)

português (PT) (101.97 KB - PDF)

**First published:**

28/08/2020

[View](/pt/documents/overview/idefirix-epar-medicine-overview_pt.pdf)

română (RO) (125.08 KB - PDF)

**First published:**

28/08/2020

[View](/ro/documents/overview/idefirix-epar-medicine-overview_ro.pdf)

slovenčina (SK) (120.55 KB - PDF)

**First published:**

28/08/2020

[View](/sk/documents/overview/idefirix-epar-medicine-overview_sk.pdf)

slovenščina (SL) (116.62 KB - PDF)

**First published:**

28/08/2020

[View](/sl/documents/overview/idefirix-epar-medicine-overview_sl.pdf)

Suomi (FI) (101.83 KB - PDF)

**First published:**

28/08/2020

[View](/fi/documents/overview/idefirix-epar-medicine-overview_fi.pdf)

svenska (SV) (101.51 KB - PDF)

**First published:**

28/08/2020

[View](/sv/documents/overview/idefirix-epar-medicine-overview_sv.pdf)

Idefirix : EPAR - Risk-management-plan

English (EN) (816.76 KB - PDF)

**First published:** 28/08/2020

**Last updated:** 02/07/2025

[View](/en/documents/rmp/idefirix-epar-risk-management-plan_en.pdf)

## Product information

Idefirix : EPAR - Product information

English (EN) (362.33 KB - PDF)

**First published:** 28/08/2020

**Last updated:** 02/07/2025

[View](/en/documents/product-information/idefirix-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-275)

български (BG) (295.91 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/bg/documents/product-information/idefirix-epar-product-information_bg.pdf)

español (ES) (183.32 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/es/documents/product-information/idefirix-epar-product-information_es.pdf)

čeština (CS) (251.6 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/cs/documents/product-information/idefirix-epar-product-information_cs.pdf)

dansk (DA) (198.79 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/da/documents/product-information/idefirix-epar-product-information_da.pdf)

Deutsch (DE) (190.02 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/de/documents/product-information/idefirix-epar-product-information_de.pdf)

eesti keel (ET) (174.52 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/et/documents/product-information/idefirix-epar-product-information_et.pdf)

ελληνικά (EL) (417.5 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/el/documents/product-information/idefirix-epar-product-information_el.pdf)

français (FR) (369.77 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/fr/documents/product-information/idefirix-epar-product-information_fr.pdf)

hrvatski (HR) (425.01 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/hr/documents/product-information/idefirix-epar-product-information_hr.pdf)

íslenska (IS) (304.16 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/is/documents/product-information/idefirix-epar-product-information_is.pdf)

italiano (IT) (356.77 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/it/documents/product-information/idefirix-epar-product-information_it.pdf)

latviešu valoda (LV) (410.11 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/lv/documents/product-information/idefirix-epar-product-information_lv.pdf)

lietuvių kalba (LT) (275.36 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/lt/documents/product-information/idefirix-epar-product-information_lt.pdf)

magyar (HU) (433.33 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/hu/documents/product-information/idefirix-epar-product-information_hu.pdf)

Malti (MT) (286.5 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/mt/documents/product-information/idefirix-epar-product-information_mt.pdf)

Nederlands (NL) (347.02 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/nl/documents/product-information/idefirix-epar-product-information_nl.pdf)

norsk (NO) (379.31 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/no/documents/product-information/idefirix-epar-product-information_no.pdf)

polski (PL) (417.57 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/pl/documents/product-information/idefirix-epar-product-information_pl.pdf)

português (PT) (362.7 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/pt/documents/product-information/idefirix-epar-product-information_pt.pdf)

română (RO) (413.7 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/ro/documents/product-information/idefirix-epar-product-information_ro.pdf)

slovenčina (SK) (429.37 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/sk/documents/product-information/idefirix-epar-product-information_sk.pdf)

slovenščina (SL) (417.58 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/sl/documents/product-information/idefirix-epar-product-information_sl.pdf)

Suomi (FI) (185.19 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/fi/documents/product-information/idefirix-epar-product-information_fi.pdf)

svenska (SV) (348.23 KB - PDF)

**First published:**

28/08/2020

**Last updated:**

02/07/2025

[View](/sv/documents/product-information/idefirix-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0000249767 25/06/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Idefirix : EPAR - All authorised presentations

English (EN) (11.01 KB - PDF)

**First published:** 28/08/2020

[View](/en/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-744)

български (BG) (32.63 KB - PDF)

**First published:**

28/08/2020

[View](/bg/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_bg.pdf)

español (ES) (10.89 KB - PDF)

**First published:**

28/08/2020

[View](/es/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_es.pdf)

čeština (CS) (27.01 KB - PDF)

**First published:**

28/08/2020

[View](/cs/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (10.76 KB - PDF)

**First published:**

28/08/2020

[View](/da/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (10.87 KB - PDF)

**First published:**

28/08/2020

[View](/de/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (10.72 KB - PDF)

**First published:**

28/08/2020

[View](/et/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (31.41 KB - PDF)

**First published:**

28/08/2020

[View](/el/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_el.pdf)

français (FR) (10.75 KB - PDF)

**First published:**

28/08/2020

[View](/fr/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (24.45 KB - PDF)

**First published:**

28/08/2020

[View](/hr/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (11.07 KB - PDF)

**First published:**

28/08/2020

[View](/is/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_is.pdf)

italiano (IT) (10.86 KB - PDF)

**First published:**

28/08/2020

[View](/it/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (29.17 KB - PDF)

**First published:**

28/08/2020

[View](/lv/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (25.37 KB - PDF)

**First published:**

28/08/2020

[View](/lt/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (17.79 KB - PDF)

**First published:**

28/08/2020

[View](/hu/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (28.83 KB - PDF)

**First published:**

28/08/2020

[View](/mt/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (10.81 KB - PDF)

**First published:**

28/08/2020

[View](/nl/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (97.58 KB - PDF)

**First published:**

28/08/2020

[View](/no/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_no.pdf)

polski (PL) (28.88 KB - PDF)

**First published:**

28/08/2020

[View](/pl/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_pl.pdf)

português (PT) (10.83 KB - PDF)

**First published:**

28/08/2020

[View](/pt/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_pt.pdf)

română (RO) (28.19 KB - PDF)

**First published:**

28/08/2020

[View](/ro/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (25.92 KB - PDF)

**First published:**

28/08/2020

[View](/sk/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (17.35 KB - PDF)

**First published:**

28/08/2020

[View](/sl/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (10.81 KB - PDF)

**First published:**

28/08/2020

[View](/fi/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (10.82 KB - PDF)

**First published:**

28/08/2020

[View](/sv/documents/all-authorised-presentations/idefirix-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Idefirix Active substance imlifidase International non-proprietary name (INN) or common name imlifidase Therapeutic area (MeSH)

- Desensitization, Immunologic
- Kidney Transplantation

Anatomical therapeutic chemical (ATC) code L04AA

### Pharmacotherapeutic group

Immunosuppressants

### Therapeutic indication

Idefirix is indicated for desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. The use of Idefirix should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.

## Authorisation details

EMA product number EMEA/H/C/004849

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Conditional approval

This medicine received a conditional marketing authorisation. This was granted in the interest of public health because the medicine addresses an unmet medical need and the benefit of immediate availability outweighs the risk from less comprehensive data than normally required. For more information, see [Conditional marketing authorisation](/node/68774) .

Orphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see [Orphan designation](/node/69983) .

PRIME: priority medicine

This medicine was granted entry to the EMA Priority Medicines (PRIME) scheme during its development. PRIME is a scheme launched by EMA to enhance support for the development of medicines that target an unmet medical need. This voluntary scheme is based on enhanced interaction and early dialogue with developers of promising medicines, to optimise development plans and speed up evaluation so these medicines can reach patients earlier. For more information, see [PRIME: priority medicines](/node/69853) .

Marketing authorisation holder

Hansa Biopharma AB

P.O. Box 785

Opinion adopted 25/06/2020 Marketing authorisation issued 25/08/2020 Revision 8

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Idefirix : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (163.28 KB - PDF)

**First published:** 02/07/2025

[View](/en/documents/procedural-steps-after/idefirix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

Idefirix : EPAR - Procedural steps taken and scientific information after the authorisation (archive)

English (EN) (161.02 KB - PDF)

**First published:** 31/08/2021

**Last updated:** 02/07/2025

[View](/en/documents/procedural-steps-after/idefirix-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf)

## Initial marketing authorisation documents

Idefirix : Orphan maintenance assessment report (initial authorisation)

Adopted

Reference Number: EMADOC-1700519818-487855

English (EN) (302.97 KB - PDF)

**First published:** 28/08/2020

[View](/en/documents/orphan-maintenance-report/idefirix-orphan-maintenance-assessment-report-initial-authorisation_en.pdf)

Idefirix : EPAR - Public assessment report

Adopted

Reference Number: EMA/372587/2020 Rev 1

English (EN) (2.44 MB - PDF)

**First published:** 28/08/2020

[View](/en/documents/assessment-report/idefirix-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Idefirix

Adopted

Reference Number: EMA/178706/2020

English (EN) (166.42 KB - PDF)

**First published:** 26/06/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-idefirix_en.pdf)

#### News on Idefirix

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2020) 26/06/2020

[New treatment to enable kidney transplant in highly sensitised patients](/en/news/new-treatment-enable-kidney-transplant-highly-sensitised-patients) 26/06/2020

#### More information on Idefirix

- [EU/3/16/1826 - orphan designation for prevention of graft rejection following solid organ transplantation](/en/medicines/human/orphan-designations/eu-3-16-1826)
- [EMEA-002183-PIP01-17-M01 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-002183-pip01-17-m01)

**This page was last updated on** 02/07/2025

## Share this page

[Back to top](#main-content)